Clinical Trial Detail

NCT ID NCT03247088
Title Study Of Sorafenib Added To Busulfan And Fludarabine Conditioning Regimen In Patients With Relapsed/Refractory AML Undergoing Stem Cell Transplantation
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

acute myeloid leukemia

Therapies

Busulfan + Fludarabine + Sorafenib

Cyclophosphamide

Tacrolimus

Filgrastim

Age Groups: senior adult

No variant requirements are available.